tbuckley/cabot-search huggingface dataset:
The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045
Authors: Allini Mafra, Mathieu Laversanne, Rafael Marcos-Gragera, Humberto V S Chaves, Charlene Mcshane, Freddie Bray, Ariana Znaor
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Background Multiple myeloma (MM) is an important hematological malignancy in older adults, with a relatively poor prognosis. We aimed to present the current global patterns of incidence and mortality from MM, and predict new cancer cases and deaths by 2045. Methods Estimated numbers of MM cases and deaths and age-standardized (World) incidence and mortality rates per 100 000 people were obtained from the GLOBOCAN 2022 database covering 185 countries. Based on the incidence and mortality rates for 2022 and UN population estimates up to 2045, cases and deaths were predicted up to 2045. Findings Globally, 188 000 MM cases and 121 000 deaths were estimated in 2022. Eastern Asia and Northern America accounted for one-fifth of all cases each (21% and 19% respectively), followed by South-Central Asia (11%), and Western Europe (9%). The incidence rates were higher in men than in women with similar geographical patterns. While the incidence rates were highest in Northern America and Australia/New Zealand (≥4/100 000 for both sexes combined), the highest mortality rates (1.8/100 000) were found in Australia/New Zealand, Northern Europe, and Southern Africa. In the absence of changing rates, the estimated incidence and mortality of MM will increase by 71% and 79%, respectively by 2045 relative to 2022. Interpretation Our study highlights the substantial burden and variations in MM incidence and mortality reflecting global disparities in diagnosis and treatment. Improved surveillance and better disease control is needed to mitigate the global impact of MM in the presence of population aging and growth.
CXCR4-targeted sensitive magnetic particle imaging for abdominal aortic aneurysm early detection and prognosis evaluation by recognizing total inflammatory cells
Authors: Genmao Cao, Ruijing Zhang, Xiaohua Jia, Bo Jiang, Yaling Li, Xuezhen Xuan, Jie Tian, Hui Hui, Shijie Xin, Honglin Dong
Journal: Cardiovascular Research (2024)

Abstract Aims The maximum aortic diameter remains the diagnostic criteria and the indicator for prognosis prediction of abdominal aortic aneurysms (AAAs). An additional imaging modality is currently needed to help evaluate the prognosis of AAA as well as early detection of AAA formation. This study evaluated the most effective inflammatory markers for AAA using single-cell sequencing and, from these, developed probes to facilitate in vivo multimodal imaging of AAA inflammation. Methods and results Single-cell RNA sequencing (scRNAseq) of the human aortic aneurysms, GSE155468 and GSE166676 data sets, identified CXCR4 as the most representative marker. Anti-CXCR4-PE antibody was conjugated to superparamagnetic iron oxide nanoparticles to synthesize Fe3O4-anti-CXCR4-PE probes. The biocompatibility and specificity of the probes were validated in vivo and in vitro. Magnetic particle imaging (MPI) and fluorescence imaging (FLI) were performed to assess inflammation in early and advanced AAA mouse models. CXCR4-specific receptor inhibitor, AMD3100, was used for confirming CXCR4 as an excellent target for AAA imaging and therapy. scRNAseq indicated that chemokine-related pathways were upregulated in aortic aneurysms, and CXCR4 was the chemokine receptor that marks all AAA-related immune cells and inflammatory vascular cells. Fe3O4-anti-CXCR4-PE effectively recognized immune cells and inflammatory vascular cells, as strong MPI and FLI signals corresponded to increased CXCR4, CD45, and CD68 levels that represented AAA severity and rupture risk. Importantly, Fe3O4-anti-CXCR4-PE can help identify early AAA formation when ultrasound is undiagnosable. Finally, AMD3100 treatment in AAA mouse model inhibited AAA expansion and rupture and reduced aortic wall inflammation by inhibiting accumulation of immune cells and haematopoietic stem cells. Conclusion CXCR4 marks immune cells and inflammatory vascular cells in AAA and is associated with AAA prognosis in a mouse model of AAA. CXCR4-targeting multimodal MPI/FLI provides a novel approach for AAA prognosis prediction and early detection.
The m6A demethylase ALKBH5 is a novel epigenetic regulator of aortic valve calcification
Authors: Yueheng Wang, Shengping He, Lan Lan, Hongjiao Yu, Huan Zhao, Yuchen Xie, Guoli Zhong, Liang Yuan, Kun Li, Xiao Hu, Vicky E Macrae, Xiaodong Fu, Guojun Chen, Dongxing Zhu
Journal: Cardiovascular Research (2024)

Calcific aortic valve disease (CAVD) is a common heart valve disease with significant clinical consequences. The mechanisms that drive the pathogenesis of CAVD remain to be fully elucidated. N6-methyladenosine (m6A), the most prevalent RNA epigenetic regulator, has recently been implicated in cardiovascular disease, but its role in CAVD has yet to be investigated. In this study, we investigated the potential function of m6A modification in CAVD. Using clinical samples from CAVD patients in combination with human valve interstitial cell (hVIC) calcification model, we screened the expression of m6A modulators and discovered that ALKBH5 alkB homolog 5, RNA demethylase (ALKBH5), a key m6A demethylase, was significantly down-regulated in calcified hVICs and human aortic valves. Consistently, increased m6A levels were seen in calcified hVICs, and treated with 3-deazaadenosine (DAA), an inhibitor of m6A modification, significantly reduced hVIC osteogenic differentiation and calcification. In addition, we showed that silencing of ALKBH5 expression increased global m6A levels, and accelerated hVIC osteogenic differentiation and calcification, whereas overexpression of ALKBH5 resulted in the opposite effect. We demonstrated that ALKBH5 directly modulate m6A levels of TGFBR2 and its mRNA stability, leading to altered TGFBR2 expression and SMAD2 signaling in hVICs. We further showed that inhibition of TGFBR2 or knockdown of SMAD2 attenuated ALKBH5 knockdown-induced hVIC osteogenic differentiation and calcification. The expression of the m6A reader protein YTH N6-methyladenosine RNA binding protein F1 (YTHDF1) was upregulated during the process of hVIC calcification. Intriguingly, we revealed that the ALKBH5 silencing-induced increased hVIC osteogenic differentiation and calcification were abolished after knockdown of YTHDF1. These data suggest a potential role YTHDF1 in aortic valve calcification. This study showed that ALKBH5 attenuated aortic valve calcification through the TGFBR2/SMAD2 signaling pathway via direct m6A modification of TGFBR2. .
Cardiorespiratory fitness is associated with cognitive function in late adulthood: baseline findings from the IGNITE study
Authors: Lauren E Oberlin, Lu Wan, Chaeryon Kang, Allison Romano, Sarah Aghjayan, Alina Lesnovskaya, Hayley S Ripperger, Jermon Drake, Rae Harrison, Audrey M Collins, Cristina Molina-Hidalgo, George Grove, Haiqing Huang, Arthur Kramer, Charles H Hillman, Jeffrey M Burns, Eric D Vidoni, Edward McAuley, M Ilyas Kamboh, John M Jakicic, Kirk I Erickson
Journal: British Journal of Sports Medicine (2024)

To evaluate the association between cardiorespiratory fitness (CRF) and cognition in a large sample of older adults, and to examine clinical and demographic factors that might moderate these associations.
Reproducibility of quantitative myocardial perfusion and coronary flow capacity by positron emission tomography: 3D digital SiPM solid state versus legacy 2D analog systems for clinical practice and trials
Authors: Amanda Roby, Lindsey Harmon, Kelly Sander, Linh Bui, Danai Kitkungvan, Monica Patel, Jagat Narula, Nils P Johnson, K Lance Gould
Journal:  (2024)

Abstract Aims Quantitative rest–stress myocardial perfusion in millilitres per minute per gram among multiple 2D and 3D positron emission tomography–computed tomography (PET-CT) scanners is essential for personalized cardiac management and clinical trials. Accordingly, this study reports the accuracy and precision of quantitative rest–stress millilitres per minute per gram and coronary flow capacity among 2D and two different digital 3D silicon photomultiplier (SiPM) PET-CT scanners for quantifying the severity of coronary pathophysiology for clinical trials or guiding interventions vs. medical treatment. Methods and results One hundred seventy-one participants underwent 748 paired serial rest or stress PET perfusion imaging in the same person on ‘same day’ or ‘different days’ using rubidium-82 (Rb-82) pharmacologic stress on 2D and two different digital 3D SiPM PET-CT scanners for global myocardial perfusion in millilitres per minute per gram. For methodological variability of 66 ‘same-day’ serial paired PETs in the same person by 2D and two different 3D SiPM PET-CT scanners, rest–stress global myocardial millilitres per minute per gram had no significant bias (P = 0.464, mean difference 0.014 ± 0.21 mL/min/g) with coefficient of variation (COV) of ±14%. For methodological plus biological variability of 154 ‘different-day’ serial paired PETs, rest–stress global perfusion had no significant bias (P = 0.136), mean difference (0.028 ± 0.33), and COV of ±20%. Coronary flow reserve had a small bias of 0.095 ± 0.57 (P = 0.041) and COV of ±20%. Coronary flow capacity was not different by Kolmogorov–Smirnov test (P = 0.99). Conclusion For quantifying myocardial perfusion in the same person on ‘same day’ or ‘different days’ using Rb-82, 3D SiPM PET-CT is comparably reproducible to analogue 2D PET-CT with the HeartSee perfusion model as the basis for quantifying physiologic severity of coronary heart disease to guide clinical decision-making or randomized clinical trials confirming these outcomes.
Is High-Flow Oxygen the Standard for All Patients With Acute Respiratory Failure?
Authors: Jean-Pierre Frat, Sylvain Le Pape, Arnaud W. Thille
Journal: JAMA (2024)

RENOVATE Investigators and the BRICNet Authors; Fabiano Francio; Renata Monteiro Weigert; Edna Daldania Biolchi Mattei; Cintia Magalhaes Carvalho Grion; Josiane Festti; Ana Luiza Mezzaroba; Ary Serpa Neto; Karina T. Timenetsky; Adriana Maria Simoes Orfao Nogueira; Marcus Vinicius Camargo Brito; Iuri Dheloi Oliveira Lima; Rodrigo Alexandre Dona; Marina Monica Bahl Mafra; Ana Carolina Starke; Thiago Lisboa; Caroline Fachini; André Torelly; Rodrigo Santos Biondi; Andre Luiz Nascimento Souza; Anderson Luiz Mendes Fernandes; Gustavo Neves Araujo; Vicente Ponte; Maria Helena Moraes Antunes; Fabio Fernandes Cardoso Cardoso; Alice Bertotto Poersch; Yuri Carlotto Ramires; Lúcio Roberto Requiao Moura; Maria Bethania Peruzzo; Jonas Sposito; Daniele Martins Piekala; Iuri Christmann Wawrzeniak; Léa Fialkow; Marcela Dutra; Maiara Suelen Mazera; Cassia Pimenta Barufi Martins; Daniela Helena Machado Freitas; Luciana Coelho Sanches; Maísa Guimarães de Castro Pereira; Mariana Regina Cunha; Israel S. Maia, MD, PhD; Letícia Kawano-Dourado, MD, PhD; Lucas Tramujas, MD; Neymar Elias de Oliveira, MD; Rafael Naoki Souza, RT; Dhaisi Faustino Signorini, RT; Mariangela Pimentel Pincelli, MD, PhD; Cássio Luis Zandonai, RT; Regiane Tamires Blasius, RT; Fabrício Freires, RT; Vanessa Marques Ferreira, RT; Marcelo Luz Pereira Romano, MD, PhD; Mieko Claudia Miura, MSc; Caroline Maschio de Censo, MSc; Eliana Bernadete Caser, MD, PhD; Betania Silva, RT; Daniela Correia Santos Bonomo, RT; Jussara Alencar Arraes, MSc; Meton Soares de Alencar Filho, MD; Jacques Gabriel Álvares Horta, MD; Déborah Campos Oliveira, RT; Emerson Boschi, MD, MSc; Rafael Lessa Costa, MD; Glauco Adrieno Westphal, MD, PhD; Juliano Ramos, MD; Fábio Holanda Lacerda, MD; Conrado Roberto Hoffmann Filho, MD; Bruno Valle Pinheiro, MD, PhD; Leonardo Bugarin de Andrade Neumamm, PhD; Mário Roberto Rezende Guimarães Júnior, MD; Davi Tamamaru de Souza, MD, MSc; Juliana Carvalho Ferreira, MD, PhD; Louis Nakayama Ohe, MD; Daniel Almeida Schettini, MD, MSc; Marlus Muri Thompson, MD; Maria Cristina França de Oliveira, MD; Viviane Cordeiro Veiga, MD, PhD; Karina L. Negrelli, DVM; Renato H. N. Santos, BSc(Stat); Lucas Damiani, PhD; Rodrigo M. Gurgel, Biomed Sci; Samara P. C. Gomes, Biomed Sci; Lucas M. Lima, BScIT; Tamiris A. Miranda, MSc; Ligia N. Laranjeira, PhD; Pedro Gabriel Melo de Barros e Silva, MD, PhD; Flávia R. Machado, MD, PhD; Mark Fitzgerald, PhD; Anna Bosse, MS; Joe Marion, PhD; Carlos Roberto Ribeiro Carvalho, MD, PhD; Laurent Brochard, MD, PhD; Roger J. Lewis, MD, PhD; Alexandre Biasi Cavalcanti, MD, PhD
Reevaluating Respiratory Support in Acute Respiratory Failure—Insights From the RENOVATE Trial and Implications for Practice
Authors: Yonathan Freund, Amelie Vromant
Journal: JAMA (2024)

RENOVATE Investigators and the BRICNet Authors; Fabiano Francio; Renata Monteiro Weigert; Edna Daldania Biolchi Mattei; Cintia Magalhaes Carvalho Grion; Josiane Festti; Ana Luiza Mezzaroba; Ary Serpa Neto; Karina T. Timenetsky; Adriana Maria Simoes Orfao Nogueira; Marcus Vinicius Camargo Brito; Iuri Dheloi Oliveira Lima; Rodrigo Alexandre Dona; Marina Monica Bahl Mafra; Ana Carolina Starke; Thiago Lisboa; Caroline Fachini; André Torelly; Rodrigo Santos Biondi; Andre Luiz Nascimento Souza; Anderson Luiz Mendes Fernandes; Gustavo Neves Araujo; Vicente Ponte; Maria Helena Moraes Antunes; Fabio Fernandes Cardoso Cardoso; Alice Bertotto Poersch; Yuri Carlotto Ramires; Lúcio Roberto Requiao Moura; Maria Bethania Peruzzo; Jonas Sposito; Daniele Martins Piekala; Iuri Christmann Wawrzeniak; Léa Fialkow; Marcela Dutra; Maiara Suelen Mazera; Cassia Pimenta Barufi Martins; Daniela Helena Machado Freitas; Luciana Coelho Sanches; Maísa Guimarães de Castro Pereira; Mariana Regina Cunha; Israel S. Maia, MD, PhD; Letícia Kawano-Dourado, MD, PhD; Lucas Tramujas, MD; Neymar Elias de Oliveira, MD; Rafael Naoki Souza, RT; Dhaisi Faustino Signorini, RT; Mariangela Pimentel Pincelli, MD, PhD; Cássio Luis Zandonai, RT; Regiane Tamires Blasius, RT; Fabrício Freires, RT; Vanessa Marques Ferreira, RT; Marcelo Luz Pereira Romano, MD, PhD; Mieko Claudia Miura, MSc; Caroline Maschio de Censo, MSc; Eliana Bernadete Caser, MD, PhD; Betania Silva, RT; Daniela Correia Santos Bonomo, RT; Jussara Alencar Arraes, MSc; Meton Soares de Alencar Filho, MD; Jacques Gabriel Álvares Horta, MD; Déborah Campos Oliveira, RT; Emerson Boschi, MD, MSc; Rafael Lessa Costa, MD; Glauco Adrieno Westphal, MD, PhD; Juliano Ramos, MD; Fábio Holanda Lacerda, MD; Conrado Roberto Hoffmann Filho, MD; Bruno Valle Pinheiro, MD, PhD; Leonardo Bugarin de Andrade Neumamm, PhD; Mário Roberto Rezende Guimarães Júnior, MD; Davi Tamamaru de Souza, MD, MSc; Juliana Carvalho Ferreira, MD, PhD; Louis Nakayama Ohe, MD; Daniel Almeida Schettini, MD, MSc; Marlus Muri Thompson, MD; Maria Cristina França de Oliveira, MD; Viviane Cordeiro Veiga, MD, PhD; Karina L. Negrelli, DVM; Renato H. N. Santos, BSc(Stat); Lucas Damiani, PhD; Rodrigo M. Gurgel, Biomed Sci; Samara P. C. Gomes, Biomed Sci; Lucas M. Lima, BScIT; Tamiris A. Miranda, MSc; Ligia N. Laranjeira, PhD; Pedro Gabriel Melo de Barros e Silva, MD, PhD; Flávia R. Machado, MD, PhD; Mark Fitzgerald, PhD; Anna Bosse, MS; Joe Marion, PhD; Carlos Roberto Ribeiro Carvalho, MD, PhD; Laurent Brochard, MD, PhD; Roger J. Lewis, MD, PhD; Alexandre Biasi Cavalcanti, MD, PhD
From onset to advancement: the temporal spectrum of α-synuclein in synucleinopathies
Authors: James A Wiseman, Kreesan Reddy, Birger Victor Dieriks
Journal: Ageing Research Reviews (2024)

This review provides an in-depth analysis of the complex role of alpha-synuclein (α-Syn) in the development of α-synucleinopathies, with a particular focus on its structural diversity and the resulting clinical variability. The ability of α-Syn to form different strains or polymorphs and undergo various post-translational modifications significantly contributes to the wide range of symptoms observed in disorders such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), as well as in lesser-known non-classical α-synucleinopathies. The interaction between genetic predispositions and environmental factors further complicates α-synucleinopathic disease pathogenesis, influencing the disease-specific onset and progression. Despite their common pathological hallmark of α-Syn accumulation, the clinical presentation and progression of α-synucleinopathies differ significantly, posing challenges for diagnosis and treatment. The intricacies of α-Syn pathology highlight the critical need for a deeper understanding of its biological functions and interactions within the neuronal environment to develop targeted therapeutic strategies. The precise point at which α-Syn aggregation transitions from being a byproduct of initial disease triggers to an active and independent driver of disease progression - through the propagation and acceleration of pathogenic processes - remains unclear. By examining the role of α-Syn across various contexts, we illuminate its dual role as both a marker and a mediator of disease, offering insights that could lead to innovative approaches for managing α-synucleinopathies.
Challenging underwater endoscopic mucosal resection of duodenal adenoma successfully achieved with combination of therapeutic pediatric colonoscope and retroflexion
Authors: Amina Abdulle, Mathieu Pioche, Melissa Gruner, Alexandru Lupu, Gwladys Pointet, Pierre Lafeuille, Jérôme Rivory
Journal: Endoscopy (2024)

Nonampullary duodenal adenomas are rare, detected in only 0.1%–0.4% of patients undergoing esophagogastroduodenoscopy (EGD) [1]. The European Society of Gastrointestinal Endoscopy (ESGE) recommends that all duodenal adenomas should be considered for endoscopic resection, as progression to invasive carcinoma is highly likely [2]. Endoscopic resection has been a first choice of treatment for duodenal adenomas, but the method has not been standardized [3]. To overcome the practical difficulty of conventional endoscopic mucosal resection (EMR), underwater endoscopic mucosal resection (UEMR) has recently been developed. UEMR seems to have significantly higher R0 resection rates and lower post-procedural bleeding rates than EMR. Moreover, it seems safer than conventional EMR and has been associated with a lower incidence of recurrences [4] [5].
Successful papillary large-balloon dilation using a novel nonslip balloon catheter in a patient with Roux-en-Y gastrectomy
Authors: Yuki Tanisaka, Shomei Ryozawa, Masafumi Mizuide, Akashi Fujita, Ryuhei Jinushi, Ryuichi Watanabe, Ryo Sato
Journal: Endoscopy (2024)

Endoscopic papillary large-balloon dilation (EPLBD) [1] has been widely used to extract large stones from the bile duct in patients with Roux-en-Y gastrectomy, using a balloon enteroscope [2] [3]. However, performing EPLBD with a balloon enteroscope is challenging owing to difficulty in securing a stable scope position and the lack of a forceps elevator, which can lead to balloon slippage during inflation. To overcome these limitations, a novel nonslip balloon catheter (RIGEL; Japan Lifeline, Japan) was developed. The distal and proximal ends of the balloon inflate first, followed by the middle, to prevent the catheter from slipping in or out of the papilla. Additionally, a black elastic band is attached to the center of the balloon to aid in endoscopic confirmation of the balloon's position. It has previously demonstrated effectiveness for balloon dilation with a balloon enteroscope using a balloon with an 8-mm diameter [4] [5]. Recently, a balloon with a 12-mm diameter ([Fig. 1]) has been added to the lineup to facilitate EPLBD with a balloon enteroscope. We report a case of successful EPLBD using a novel nonslip balloon catheter in a patient with Roux-en-Y gastrectomy.
Management of an obstructed hepatoportocholecystostomy via an endoscopic cholecystoduodenostomy
Authors: Gabriel Marcellier, Paul Rivallin, Abdellah Hedjoudje, Kenza Bourhrara, Benedicte Jais, Ryad Smadhi, Frederic Prat
Journal: Endoscopy (2024)

Biliary atresia is a rare perinatal disease leading to the child's death if left untreated [1]. There are several types of biliary atresia depending on the remaining functional biliary tract [2]. The most common (75%) is type 4 with complete extrahepatic atresia; here the Kasai intervention is indicated, consisting of an anastomosis between the hepatic hilum and a Roux-en-Y loop ([Fig. 1] a) [3] [4]. In some cases (type 3, 20%), the gallbladder and cystic duct are still patent and an hepatoportocholecystostomy (or "gallbladder–Kasai" surgery) can be performed. The hilar plate is then stitched to the gallbladder, which reduces the risk of cholangitis ([Fig. 1] b) [5].
One-step endoscopic ultrasound-guided pancreatic duct drainage using a 7-Fr ultra-tapered plastic stent and a novel 0.035-inch guidewire
Authors: Takashi Sasaki, Yoichiro Sato, Yuri Maegawa, Takeshi Okamoto, Naoki Sasahira
Journal: Endoscopy (2024)

An 84-year-old woman with ampullary carcinoma was referred to our hospital ([Fig. 1]). Robotic-assisted pancreaticoduodenectomy was planned, but only choledochojejunostomy and cholecystectomy were performed because para-aortic lymph node metastasis was detected intraoperatively. The patient subsequently experienced repeated episodes of pancreatitis, and pancreatic duct drainage was planned.
Effective use of endoscopic ultrasound for diagnosing and differentiating a gastroduodenal artery aneurysm
Authors: Koichi Soga, Takeshi Fujiwara, Fuki Hayakawa, Mayumi Yamaguchi, Ikuhiro Kobori, Masaya Tamano
Journal: Endoscopy (2024)

Aneurysms of the visceral arteries represent a rare but clinically significant vascular condition, accounting for approximately 5% of all intra-abdominal aneurysms [1]. Gastroduodenal artery aneurysms are particularly uncommon, accounting for 1.5–2.0% of all visceral artery aneurysms. Clinically, gastroduodenal artery aneurysms can present with abdominal pain and hematemesis and carry a high risk of rupture [2]. Symptoms of a gastroduodenal artery aneurysm may vary from incidental findings on a computed tomography (CT) scan to life-threatening hemorrhage due to rupture, necessitating prompt diagnosis and intervention [3].
The role of HPV16 in oral cavity and laryngeal cancers in the United States
Authors: Christine M Kava, Anil K Chaturvedi, Virginia Senkomago, Jacqueline M Mix, Lauri E Markowitz, Aimée R Kreimer, Elizabeth R Unger, Mona Saraiya
Journal: JNCI Journal of the National Cancer Institute (2024)

In addition to oropharyngeal cancers, evidence suggests there may be an etiologic role for human papillomavirus (HPV) in some other head and neck cancers arising from the oral cavity and larynx. We estimated the burden of HPV16-attributable cancers of the oral cavity (ICD-O-3 site codes C02.0-C02.3, C02.9, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C05.8, C05.9, C06.0-C06.2, C06.8, C06.9) and larynx (C32.0-C32.3, C32.8, C32.9) in the United States by pooling estimates from published case studies to calculate HPV16-attributable fractions (HPV16-AFs) and applying the HPV16-AFs to 2016-2020 US Cancer Statistics data. During 2016-2020, of an average annual number of 12,612 oral cavity cancers, 3.9% (n = 497) were estimated to be attributable to HPV16. Of an average annual number of 11,170 laryngeal cancers, 2.8% (n = 309) were estimated to be attributable to HPV16. This information can improve surveillance of HPV16-attributable cancers in the US population and inform our understanding of the potential impact of HPV vaccination on cancers at these two sites.
Hematemesis and gastric pseudo-obstruction secondary to an iatrogenic diaphragmatic hernia
Authors: Kui Xu, Fan Wang, Yan-Min Yang, Xiao Yuan, Chao-Chao Yang, Xiang-Lin Hao, Cong Yuan
Journal: Endoscopy (2024)

A 29-year-old woman was referred with recurrent nonbilious vomiting for 2 weeks and fresh hematemesis for the past 12 hours. Her past medical history included left nephrectomy, splenectomy, and partial diaphragmatic resection and repair 3 years previously owing to left renal tuberculosis with extensive adhesions.